The KOL Insight report, published September 23, 2024 and updated November 11, 2024, summarizes views from 12 lung-cancer specialists in North America and Europe on targeted therapies for non-small cell lung cancer (NSCLC).
Experts discussed how Phase III evidence is reshaping the use of osimertinib (Tagrisso) in EGFR-mutated disease.
The report describes expanding use of amivantamab (Rybrevant) beyond narrower patient groups, while noting toxicity as a treatment challenge.
Trastuzumab deruxtecan (Enhertu) was seeing limited but growing uptake for HER2-mutant NSCLC.
The report focuses on treatment pathways, unmet needs, and emerging market trends; it is a specialist insight report rather than a newly announced clinical result.
More recent developments in the search results include 2025 news on HER2-targeted drug zongertinib and 2026 reporting on targeted NSCLC therapies, but those are separate from the 2024 KOL Insight report.
Sources:
Non-Small Cell Lung Cancer - Targeted Therapies - KOL Insight
Non-Small Cell Lung Cancer Treatment (PDQ®) - NCI
Non-Small Cell Lung Cancer - Immunotherapies - KOL Insight
Non-Small Cell Lung Cancer, Version 4.2026, NCCN ... - PubMed
Targeted therapy for non–small cell lung cancer
Targeted Drug Therapy for Non-small Cell Lung Cancer
Frontiers | Non-small cell lung cancer research: advances and persistent challenges
Non-Small Cell Lung Cancer (NSCLC) KOL Interview - Germany
Non-Small Cell Lung Cancer (NSCLC) Interview - UK - Biomedtracker
Non-Small Cell Lung Cancer (NSCLC) - Market Insight ...
New Lung Cancer Treatments Aim To Reduce Deaths and Improve ...
CASE-BASED ROUNDTABLE SERIES | undefined
Non-Small Cell Lung Cancer Pipeline Drugs Insights Report
Sacituzumab Tirumotecan + Pembrolizumab Extends PFS in NSCLC